

Blanks in the dataset represent missing data		
Variable	Label	Description
USI	USI ID	
eligible	Eligibility of the study	0=No; 1=Yes
eligible_evaluable	Eligible, evaluable patients on study	0=No; 1=Yes
vhr	VHR ALL features	0=No; 1=Yes
rand_evaluable	Eligible, evaluable, randomized subjects (eligible, evaluable for post induction therapy, and not VHR, not DS)	0=No; 1=Yes
gender	Gender	1=Male; 2=Female
race_cat	Race	1=American Indian or Alaska Native; 2=Asian; 3=Native Hawaiian or other Pacific Islander; 4=Black or African American; 5=White; 98=Other; 99=Unknown
ethnic_cat	Ethnicity	1=Hispanic or Latino; 2=Not Hispanic or Latino; 3=Unknown
wbc	Number of white blood cells ($\times 10^3$ /MicroLiter)	
down_syndrome	Down Syndrome	0=No; 1=Yes
age_yrs	Age at diagnosis (years)	
cns	Central nervous system status	1=CNS 1; 2=CNS 2; 3=CNS 3
RER	Determine response	0=Slow early responder (SER); 1=Rapid early responder (RER)
bcr	BCR-ABL fusion transcript determined by Fish or RT-PCR	0=No; 1=Yes
mll	MLL rearrangement	0=No; 1=Yes
hypodiploid	Hypodiploid	0=No; 1=Yes

stratum	Stratum	1=No CNS 3, no testicular disease, no Down syndrome and (either no steroid pretreatment or steroid pre-treatment <48 hours during the week preceeding diagnosis); 2=CNS 3 and /or testicular disease and/or steroid pre-treatment >48 hours during the week preceeding diagnosis and (No Down Syndrome); 3=Down Syndrome and No CNS 3 and No testicular, and (either no steroid pretreatment or steroid pre-treatment <48 hours during the week preceeding diagnosis); 4=Down Syndrome and (CNS 3 and/or testicular disease)and (either no steroid pretreatment or steroid pre-treatment <48 hours during the week preceeding diagnosis); 5=All Down Syndrome Patients; 6=Age 1 -9 yrs (No CNS 3, no testicular disease and either no steroid pretreatment or steroid pre-treatment less than 48 hrs during the week preceding diagnosis); 7=Age 1-9 yrs (CNS 3 and /or testicular disease and/or steroid pre-treatment greater than 48 hours during the week preceding diagnosis); 8=Age 10+ yrs (No CNS 3, no testicular disease and either no steroid pretreatment or steroid pre-treatment less than 48 hrs during the week preceding diagnosis); 9=Age 10+ yrs (CNS 3 and /or testicular disease and/or steroid pre-treatment greater than 48 hours during the week preceding diagnosis)
trt	Treatment	1=(DC) 2 weeks Dexamethasone during Induction, Capizzi Methotrexate during Interim Maintenance I; 2=(DH) 2 weeks Dexamethasone during Induction, High Dose Methotrexate during Interim Maintenance I; 3=(PC) 4 weeks Prednisone during Induction, Capizzi Methotrexate during Interim Maintenance I; 4=(PH) 4 weeks Prednisone during Induction, High Dose Methotrexate during Interim Maintenance I
randomized	Subjects were randomized to the four treatment regimens; PC, PH, DC, DH	0=No; 1=Yes
evaluable_induction	Evaluable for Induction	0=No; 1=Yes
evaluable_post_induction	Evaluable for Post-Induction	0=No; 1=Yes

BM_day29	Bone marrow status at end Induction	1=M1: <5% lymphoblasts; 2=M2: 5-25% lymphoblasts; 3=M3: >25% lymphoblasts; 5=Not Available
MRD_day29_pct	Minimal Residual Disease (MRD) percentage at End Induction (%)	
MTX	Subjects randomized to Methotrexate (HD-MTX versus C-MTX)	0=Capizzi methotrexate; 1=High Dose methotrexate
mtx_x1	EFS time for Methotrexate Randomized patients (the outcome of those randomized to C-MTX who subsequently received HD-MTX was censored at the time of therapy crossover) (days)	
mtx_x2	Event-free survival (EFS) event indicator for Methotrexate Randomized patients	0=No event; 1=Had event
surv_x1	OS time (days)	
surv_x2	Overall survival (OS) event indicator	0=alive; 1=death
tx_modified	Therapy changes were recommended to provide HD-MTX to all subjects who had not yet completed course one of maintenance or received cranial irradiation	0=No; 1=Yes
event_type	Type of events	0=None; 1=Induction Failure; 2=Induction Death; 3.01=Relapse: Marrow; 3.02=Relapse: CNS; 3.03=Relapse: Testicular; 3.04=Relapse: Marrow+CNS; 3.05= Relapse: Marrow+Testicular; 3.06=Relapse: Marrow+other relapse; 3.07=Relapse: Marrow+CNS+other; 3.08= Relapse: Marrow+CNS+Testicular; 3.09=Relapse: Other; 4=SMN; 5=Death; 104=SMN (off-therapy); 105=Death (off-therapy)

Time_to_events	The time to occurrence of the first event (days) for cumulative incidence analyses	
----------------	--	--